Figure 2. Intensity of Coprescription of Opioids and Benzodiazepines Before and After the Centers for Disease Control and Prevention Guideline Release.

Adjusted proportion of opioid prescription days with overlapping benzodiazepine prescriptions in the population of commercially insured individuals (A) and Medicare Advantage beneficiaries (B). Statistical significance was set at P = .05. Statistical significance for change in level is indicated next to the dashed line, which denotes the release of the opioid guidelines. Statistical significance for change in trend (line slope) is indicated further to the right of the statistical significance of the change in level. Point estimates and 95% confidence intervals are shown in eTable 6 in the Supplement.